Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study
- Chiew-Loon Koo†1,
- Lai-Fong Kok†2,
- Ming-Yung Lee†3,
- Tina S Wu4,
- Ya-Wen Cheng5,
- Jeng-Dong Hsu1, 6,
- Alexandra Ruan7,
- Kuan-Chong Chao8Email author and
- Chih-Ping Han3, 5, 9Email author
© Koo et al; licensee BioMed Central Ltd. 2009
Received: 13 November 2008
Accepted: 14 April 2009
Published: 14 April 2009
Endocervical adenocarcinomas (ECAs) and endometrial adenocarcinomas (EMAs) are malignancies that affect uterus; however, their biological behaviors are quite different. This distinction has clinical significance, because the appropriate therapy may depend on the site of tumor origin. The purpose of this study is to evaluate 3 different scoring mechanisms of p16INK4a immunohistochemical (IHC) staining in distinguishing between primary ECAs and EMAs.
A tissue microarray (TMA) was constructed using formalin-fixed, paraffin-embedded tissue from hysterectomy specimens, including 14 ECAs and 24 EMAs. Tissue array sections were immunostained with a commercially available antibody of p16INK4a. Avidin-biotin complex (ABC) method was used for antigens visualization. The staining intensity and area extent of the IHC reactions was evaluated using the semi-quantitative scoring system. The 3 scoring methods were defined on the bases of the following: (1) independent cytoplasmic staining alone (Method C), (2) independent nucleic staining alone (Method N), and (3) mean of the sum of cytoplasmic score plus nucleic score (Method Mean of C plus N).
Of the 3 scoring mechanisms for p16INK4a expression, Method N and Method Mean of C plus N showed significant (p-values < 0.05), but Method C showed non-significant (p = 0.245) frequency differences between ECAs and EMAs. In addition, Method Mean of C plus N had the highest overall accuracy rate (81.6%) for diagnostic distinction among these 3 scoring methods.
According to the data characteristics and test effectiveness in this study, Method N and Method Mean of C plus N can significantly signal to distinguish between ECAs and EMAs; while Method C cannot do. Method Mean of C plus N is the most promising and favorable means among the three scoring mechanisms.
The histomorphologic overlap of ECA and EMA can make differentiation difficult on H&E in small pre-operative biopsy or curetting specimens. Ascertaining the site of cancer origin may be difficult, but plays an important role in guiding treatment. For the EMA, staging is surgical; however, for the primary ECA, staging is clinical. Treatment protocols may differ substantially between both of them. [1–3]
Previous studies have shown that certain immunohistochemical markers may be helpful in distinguishing between ECAs and EMAs. A traditional 3-marker panel (ER/Vim/CEA) has previously been proposed to make the distinction. A positive ER, Vim and a negative CEA result indicates an EMA; a negative ER, Vim and positive CEA result indicates an ECA. There are, however, many unexpected aberrant immunoexpressions not characteristic of either primary ECAs or EMAs. No study has identified one marker that clearly and consistently makes this distinction in all cases. [4–8]
Recent study has focused on other markers, such as p16INK4a, which may express in different intensities, staining patterns and subcellular localizations in various malignancies and tissues. It is also reported that ECAs tends to be positively and diffusely expressed by p16INK4a, whereas EMAs tends to be negatively or focally expressed by p16INK4a in routine whole-sectioned tissue slides. [9–13] To date, there is not yet consensus to define the optimal scoring methods of p16INK4a immunoexpression in various tissue samples, especially in those small sizes of pre-operative biopsy or curetting specimens of endocervix or endometrium. In this study, our objective was to propose the appropriately scoring methods and to report that these methods can be easily applied to p16INK4a immunohistochemistry (IHC) as a diagnostic adjunct in distinguishing between ECAs and EMAs. [14–18]
Materials and methods
The study material consisted of slides and selected formalin-fixed, paraffin-embedded tissue blocks from 38 hysterectomy specimens retrieved from the archives of the Tissue Bank, Clinical Trial Center, Chung-Shan Medical University Hospital. These specimens of known origin, endocervix or endometrium, were accessioned between 2004 and 2008. The cases studied included EMAs (n = 24), as well as ECAs (n = 14). Two board-certified pathologists (CP Han and LF Kok) reviewed all H&E stained slides for these cases. A slide with tumor representative was selected and circled from each case. In the next step, the area corresponding to the selected area on the slide was also circled on the block with an oil marker pen. All these donors' tissue blocks were sent to the Biochiefdom International Co. LTD, Taiwan for tissue microarray construction. They were cored with a 1.5 mm diameter needle and transferred to a recipient paraffin block. The recipient block was sectioned at 5 u m, and transferred to silanized glass slides.
Using the Avidin-Biotin Complex (ABC) technique, immunohistochemistry and antigen retrieval methods were applied in the same manner as described in previous literature. Briefly, all the 1.5 mm and 5 u m cores of tissue array specimens embedded in paraffin slice on coated slides, were washed in xylene to remove the paraffin, rehydrated through serial dilutions of alcohol, followed by washings with a solution of PBS (pH 7.2). All subsequent washes were buffered via the same protocol. Treated sections were then placed in a citrate buffer (pH 6.0) and heated in a microwave for two 5-minute sessions. The samples were then incubated with a monoclonal anti-mouse p16INK4a antibody (F12, sc-1661, Santa Cruz, 1:200 dilution) for 60 minutes at 25°C. The conventional streptavidin peroxidase method (DAKO, LSAB Kit K675, Copenhagen, Denmark) was performed for signal development and the cells were counter-stained with hematoxylin. Negative controls were obtained by excluding the primary antibody, and positive controls were simultaneously obtained by staining tissues of squamous cell carcinoma of uterine cervix. This slide was mounted with gum for examination and capture by the Olympus BX51 microscopic/DP71 Digital Camera System for study comparison.
Scoring of IHC staining results
The core of specimens on the tissue microarray (TMA) slides were examined and scored using a two-headed microscope. Because p16INK4a IHC scoring algorithms have not been optimized and standardized, we interpreted the cytoplasmic staining and nucleic staining separately as well as mixed cytoplasmic/nucleic staining collectively. We also adopted the German semi-quantitative scoring system in considering the staining intensity and area extent, which has been widely accepted and used in previous studies. [7–18]Every tumor was given a score according to the intensity of the nucleic or cytoplasmic staining (no staining = 0, weak staining = 1, moderate staining = 2, strong staining = 3) and the extent of stained cells (0% = 0, 1–10% = 1, 11–50% = 2, 51–80% = 3, 81–100% = 4; negative means 0% area staining, focally positive means 1–80% area staining, diffusely positive means 81–100% area staining). The final immunoreactive score was determined by multiplying the intensity scores with the extent of positivity scores of stained cells, with the minimum score of 0 and a maximum score of 12. [19–23]
The threshold for differentiating between final positive and negative immunostaining was set at 4 for interpretation. This optimal cut-off value was determined by using the receiver operating characteristic (ROC) curve analysis (Metz, 1978; Zweig & Campbell, 1993) in this study.[24, 25] Score of 4 points or greater was considered positive for p16INK4a expression. A negative stain was classified as having an immunostaining score of 0 to 3 (essentially negative) and indicated a diagnosis of an EMA; whereas a positive stain was classified as having an immunostaining score of 4 to 12 (at least moderately positive in at least 11–50% of cells) and indicated a diagnosis of an ECA. A chi-squared or Fisher's exact test was performed to test the frequency difference of p16INK4a immunostaining (positive vs. negative) between groups of two primary adenocarcinomas (ECAs vs EMAs). A nonparametric analysis of Mann-Whitney U-test was used to test the immunostaining raw scores between the two adenocarcinomas, given the fact that the analytical IHC scores were not normally distributed. In addition, we also examined associations among the 3 different scoring mechanisms, based on the subcellular localizations of p16INK4a expression, including (1) Method C, (2) Method N, and (3) Method Mean of C plus N. The nonparametric Spearman's rho correlation coefficient was used to analyze associations between pairs of these three types of p16INK4a scores. Data were analyzed using standard statistical software (SPSS, Inc., Chicago, IL). All tests were 2-sided and the significance level was 0.05.
To evaluate and compare the patterns of p16INK4a expression in making a diagnostic distinction of primary ECAs from primary EMAs, the sensitivity, specificity, accuracy, and the positive and negative predictive values (PPV and NPV respectively) were compared and displayed. Sensitivity is defined as the probability of positive p16INK4a stain in primary ECAs. Specificity is, on the other hand, defined, as the probability of negative p16INK4a stain in primary EMAs.18 Overall accuracy is the proportion of true diagnosis of ECAs and EMAs in total number of p16INK4a scoring tests. Positive predictive value is the probability that a patient with a positive p16INK4a expression has a primary adenocarcinoma of endocervical origin. Negative predictive value is the probability that a person with a negative p16INK4a expression has a primary adenocarcinoma of endometrial origin. In order to assess whether the test results were statistically different from each other based on correct diagnosis, McNemar's test was performed. A p-value < 0.05 was considered significant.
Scoring methods based on p16INK4a expression patterns and subcellular loci in ECA and EMA
Mean of C plus N
Diagnostic performance of 4 scoring methods for measuring p16INK4a expression in correctively distinguishing 14 ECA from 24 EMA
Mean of C plus N
Distinguishing between ECAs and EMAs before planning the patient treatment is clinically important. When the tumor involves both the uterine endometrium and the endocervix, it becomes difficult to distinguish the primary site of the tumor during preoperative assessment of the limited sizes of biopsy or curetting specimens. In this study, we evaluate various p16INK4a expression patterns in both ECAs and EMAs. We also investigate the most appropriate and effective p16INK4a IHC scoring methods in distinguishing these two types of gynecologic cancers in Taiwanese women. Our valuable domestic data can be extrapolated to women in general and will be helpful in referring and managing such cases worldwide.
The p16INK4a (cyclin-dependent kinase inhibitor 4) is a tumor suppressor protein that binds to cyclin-cdk4/6 complexes, which blocks kinase activity and inhibits progression to the S phase of the cell cycle in the nucleus.[10, 15, 27–35] However, interpretation of IHC data of p16INK4a staining results is complicated because of its unclear biological significance of cytoplasmic staining and lack of universal accepted algorithm in scoring methodology. Cytoplasmic reactivity is often regarded as unexpected, unspecific event. Some consider only nucleic p16INK4a labeling in tumor cells to be positive and ignore cytoplasmic staining.[16, 32] Others state that both nucleic and cytoplasmic immunoreactivities in tumor cells are characteristic and are indeed due to p16INK4a expression. [24–28] It has also been reported that strong cytoplasmic staining in mammary carcinomas is associated with negative prognostic factors, such as low differentiation, p53, Ki-67 labeling etc. We have learned that despite nucleic expression, p53 tumor suppressor protein is localized on cell cytoplasm, where it is regarded as a way of functional inactivation. [29–31] From our data, we cannot draw any conclusion yet about the biological significance of cytoplasmic p16INK4a expression. The knowledge about the functional meaning of cytoplasmic p16INK4a expression is still limited and further large-scale studies are encouraged in various human tissues and tumors.
There are a variety of IHC scoring methods including computer-based plans in literatures, and still seems to be no generally accepted protocols in research laboratories and clinical practices for rating and scoring the immunostaining results. Comparing commercially derived computer-based programs with the conventional analyses by pathologists, there are still lacks of optimized and standardized IHC scoring algorithms. As a result, the objective accuracy did not significantly improve clinical outcome measures. [33–36]
There are also various quantitative scoring mechanisms of p16INK4a expression using various cut-off thresholds in literature. Without mentioning the grading of intensity, Vallmanya Llena FR reports the cut-off point for p16INK4a expression to be 15% positively staining extent. Fregonesi PA defines the cut-off point for p16INK4a expression to be 5% cells stained positively.  Khoury T used the positive staining area >50% as a cut-off. They all took both nucleic and cytoplasmic p16INK4a IHC staining into considerations. However, Huang HY regarded any nucleic labeling of p16INK4a to be positive, irrespective of cytoplasmic staining. Kommoss S only used the nucleic staining patterns for p16INK4a evaluation. Milde-Langosch K defined the 12-tier scoring system which was also used in this study. In addition, we investigated the three p16INK4a IHC scoring mechanisms and determined the most effective means in the distinction between ECAs and EMAs. These results can potentially be applied to future clinically diagnostic techniques, when using p16INK4aimmunohistochemistry.
McCluggage WG (2003) and Mittal K (2007) stated that a diffuse, strong staining pattern of p16INK4a, involving nearly all tumor cells tends to be an ECA, whereas, focal, patchy staining pattern of p16INK4a involving 0–50% of cells tends to be an EMA in routine whole-sectioned tissue slides.[15, 17] We did not use the patchy or diffuse pattern of p16INK4a IHC staining as a diagnostically distinctive criterion between ECAs and EMAs in this TMA study, because we think that cases with primary EMA may seem to over-express p16INK4a beyond the limited 1.5 mm core area and therefore mimic a diffuse pattern of ECA primary. Instead, we preferred to use the semi-quantitative scoring system in considering the 0–3 points of staining intensity and 0–4 points of staining area extent by multiplying both, yielding a range of score 0 to 12 points. We then divided the results by an appropriate cut-off threshold of 4 to a two-tier of negative (0–3 points) or positive (4–12 points) for interpretation. The mixed cytoplasmic and nucleic stains with varying degrees of intensity and extent in the same tissue section were not uncommon. These discrepancies of p16INK4a expression in different subcellular compartments (cytoplasmic vs. nucleic) may have caused significant difficulties in the scoring process.
In this study, we defined 3 scoring mechanisms of the p16INK4a IHC expressions, as follows: (1) independent cytoplasmic staining alone, irrespective of nucleic staining (Method C), (2) independent nucleic staining alone, irrespective of cytoplasmic staining (Method N), and (3) mixed cytoplasmic with nucleic expression, using mean of the sum of cytoplasmic score plus nucleic score (Method Mean of C plus N). Of the 14 ECA and 24 EMA tissue samples in this study, we found that only 2 (Method N as well as Method Mean of C plus N) out of the total 3 scoring methods showed significant frequency differences (p < 0.05), whereas the third scoring method (Method C) did not show a significant difference (p > 0.05) in distinguishing between ECAs and EMAs. (Table 1) We can not completely yet rule out the possibility of the indigenous heterogeneity within individual tumors, leading to different p16INK4a expression patterns in various areas within the same tissue samples, because of the limited number of cases (14 ECA and 24 EMA tissues) and limited core size (1.5 mm) of the tumor specimens in TMA. However, our data showed that cytoplasmic p16INK4a expression correlated significantly with nucleic p16INK4a expression (p = 0.007) in EMAs, but not to do so (p = 0.663) in ECA. In short, cytoplasmic and nucleic staining correlates closely in EMAs, but do not in ECAs.
For the p16INK4a-marker characteristics and test effectiveness of ECA and EMA discrimination, the goal is to minimize the chance or probability of false positive and false negative results, and to maximize the probability of true positive and true negative results. According to our data, one method based on C (Method C) does not show significant frequency difference in making distinction between ECAs and EMAs (p = 0.245). The sensitivity of Method C was 35.7%, indicating a high false negative rate, whereas, the specificity of Method C is 81.0%, indicating a favorable low false positive rate. Both the negative predictive value (69.0%) and the positive predictive value (55.6%) do not provide valuable information. However, the scoring of p16INK4a expression using the other 2 mechanisms, including Method N and Method Mean of C plus N, shows significant frequency differences in making distinction between ECAs and EMAs (p < 0.05). The highest sensitivity is 78.6% using Method N, the highest specificity is 85.7% using Method Mean of C plus N, the highest negative predictive value is 85% using Method N, whereas the highest positive predictive value is 77.0% using Method Mean of C plus N. Notably, Method Mean of C plus N has the highest overall accuracy (80%).
In summary, of the three p16INK4a-scoring mechanisms, Method N and Method Mean of C plus N are useful in distinguishing these two gynecologic adenocarcinomas (ECA vs. EMA), whereas Method C is not. Using the Method Mean of C plus N in p16INK4a-marker IHC assessments, deserves the most favorable test effectiveness and performance of all, which may not only assist physicians in making adequate diagnostic distinction between ECAs and EMAs, but also help individual patients by appropriate treatment options. Despite the finite number of cases, our data provides significant and valuable reference to verify that p16INK4a with appropriate scoring mechanisms can be applied in designing the appropriately diagnostic multi-marker panels in distinguishing between ECAs and EMAs.
Although careful gross and histologic examinations usually allows a confidant distinction between ECAs and EMAs, diagnostic dilemma may occur when tumor is localized in both endometrial and endocervical biopsies, histomorphologic overlaps and preoperative imaging studies may also confuse in establishing the site of origin. True diagnosis may require the assistance of ancillary IHC stains. The p16INK4a marker tends to be positively and diffusely expressed in ECAs, but tends to be negatively or focally expressed in EMAs. However, there is still a lack of optimized consensus or standard for p16INK4a IHC scoring mechanisms. According to the scientific results in this study, we found that Method Mean of C plus N and Method N can help to distinguish between ECAs and EMAs, but Method C is of no use to do so. Based on the data characteristics and test effectiveness, Method Mean of C plus N is the most promising score-calculating means among the three p16INK4a IHC scoring mechanisms in diagnostic distinction between these two gynecologic malignancies (ECAs vs. EMAs).
List of abbreviations used
Immunohistochemistry, Method C: Independent cytoplasmic staining alone
- Method N:
Independent nucleic staining alone
- Method Mean of C plus N:
Mean of cytoplasmic score plus nucleic score.
This work was supported in parts by grants from Department of Health (DOH98-PAB-1001-E and DOH98-PAB-1009-I), Taiwan, R.O.C.
- Luran JR, Bidus MA, Elkas JC: Uterine cancer, cervical and vaginal cancer. Novak's Gynecology. Edited by: Berek RS. 2007, Lippincott Williams & Wilkins (LWW), Philadelphia, 1343-1402. 14
- Schorge JO, Knowles LM, Lea JS: Adenocarcinoma of thecervix. Curr Treat Options Oncol. 2004, 5: 119-27. 10.1007/s11864-004-0044-0.View ArticlePubMed
- Wehling M: Translational medicine: science or wishful thinking?. J Transl Med. 2008, 6: 31-10.1186/1479-5876-6-31.PubMed CentralView ArticlePubMed
- Zaino RJ: The fruits of our labors: Distinguishing endometrial from endocervical adenocarcinoma. Int J Gynecol Pathol. 2002, 24: 1-3. 10.1097/00004347-200201000-00001.View Article
- Lotze MT, Gray J: A Life in Passing: Jonathan Gray. J Transl Med. 2007, 5: 54-10.1186/1479-5876-5-54.PubMed CentralView ArticlePubMed
- Castrillon DH, Lee KR, Nucci MR: Distinction betweenendometrial and endocervical adenocarcinoma: An immunohistochemical study. Int J Gynecol Pathol. 2002, 21: 4-10. 10.1097/00004347-200201000-00002.View ArticlePubMed
- McCluggage WG, Sumathi VP, McBride HA, Patterson A: A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol. 2002, 21: 11-5. 10.1097/00004347-200201000-00003.View ArticlePubMed
- Alkushi A, Irving J, Hsu F, Dupuis B, Liu CL, Rijn M, Gilks CB: Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch. 2003, 442: 271-7.PubMed
- Yao CC, Kok LF, Lee MY, Wang PH, Wu TS, Tyan YS, Cheng YW, Kung MF, Han CP: Ancillary p16(INK4a) adds no meaningful value tothe performance of ER/PR/Vim/CEA panel in distinguishing betweenprimary endocervical and endometrial adenocarcinomas in a tissuemicroarray study. Arch Gynecol Obstet. 2009,
- Miller RT: Endocervical vs. endometrial adenocarcinoma. THE FOCUS – Immunohistochemistry. 2002, 1-2.
- Miller RT: Endocervical vs. endometrial adenocarcinoma: update on useful immunohistochemical markers. THE FOCUS – Immunohistochemistry. 2003, 1-2.
- Grayson W, Cooper K: Application of immunohistochemistry in the evaluation of neoplastic epithelial lesions of the uterine cervix and endometrium. Current Diagnostic Pathology. 2003, 9: 19-25. 10.1054/cdip.2002.0152.View Article
- Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA: Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006, 19: 1091-100.PubMed
- McCluggage WG, Jenkins D: p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol. 2003, 22: 231-5. 10.1097/01.PGP.0000055172.04957.2F.View ArticlePubMed
- Khoury T, Tan D, Wang J, Intengan M, Yang J, Alrawi S, Yan P, Byrd JC: Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma. BMC Clin Pathol. 2006, 6: 1-10.1186/1472-6890-6-1.PubMed CentralView ArticlePubMed
- Mittal K, Soslow R, McCluggage WG: Application of Immunohistochemistry to Gynecologic Pathology. Archives of Pathology and Laboratory Medicine. 2008, 132: 402-23.PubMed
- Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL, Vhen VY, Lee H: Human Papillomavirus 16/18 E6 Oncoprotein Is Expressed in Lung Cancer and Related with p53 Inactivation. Cancer Res. 2007, 15: 10686-93. 10.1158/0008-5472.CAN-07-1461.View Article
- Hanley B: Variance in multiplex suspension array assays: carryover of microspheres between sample wells. J Negat Results Biomed. 2007, 6: 6-10.1186/1477-5751-6-6.PubMed CentralView ArticlePubMed
- Cregger M, Berger AJ, Rimm DL: Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med. 2006, 130: 1026-30.PubMed
- Remmele W, Schicketanz KH: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer, Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract. 1993, 189: 862-6.View ArticlePubMed
- Matos LL, Stabenow E, Tavares MR, Ferraz AR, Capelozzi VL, Pinhal MA: Immunohistochemistry quantification by a digital computer-assisted method compared to semiquantitative analysis. Clinics. 2006, 61: 417-24. 10.1590/S1807-59322006000500008.View ArticlePubMed
- Revision B: IHC Nuclear Image Analysis User's Guide, MAN-0027. 2007, [http://www.aperio.com/documents/]
- Han CP, Lee MY, Tzeng SL, Yao CC, Wang PH, Cheng YW, Chen SL, Wu TS, Tyan YS, Kok LF: Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization. J Exp Clin Cancer Res. 2008, 27: 25-10.1186/1756-9966-27-25.PubMed CentralView ArticlePubMed
- Zweig MH, Campbell G: Receiver-Operating Characteristic (ROC) Plots: A Fundamental Evaluation Tool in Clinical Medicine. Clin Chem. 1993, 39: 561-577.PubMed
- Metz CE: Basic principles of ROC analysis. Semin Nucl Med. 1978, 8: 283-98. 10.1016/S0001-2998(78)80014-2.View ArticlePubMed
- Bodner G, Schocke MF, Rachbauer F, Seppi K, Peer S, Fierlinger A, Sununu T, Jaschke WR: Differentiation of malignant and benign musculoskeletal tumors: combined color and power Doppler US and spectral wave analysis. Radiology. 2002, 223: 410-6. 10.1148/radiol.2232010406.View ArticlePubMed
- Kamoi S, AlJuboury MI, Akin MR, Silverberg SG: Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol. 2002, 21: 217-23. 10.1097/00004347-200207000-00003.View ArticlePubMed
- Milde-Langosch K, Ocon E, Becker G, Löning T: p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hypermethylation or mutation in endometrioid and mucinous tumors. Int J Cancer. 1998, 79: 61-5. 10.1002/(SICI)1097-0215(19980220)79:1<61::AID-IJC12>3.0.CO;2-K.View ArticlePubMed
- Milde-Langosch K, Riethdorf L, Bamberger A-M, Löning T: P16/MTS1 and pRb expression in endometrial carcinomas. Virchows Arch. 1999, 434: 23-28. 10.1007/s004280050300.View ArticlePubMed
- Camp RL, Chung GG, Rimm DL: Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002, 8: 1323-7. 10.1038/nm791.View ArticlePubMed
- Bradley KT, Budnick SD, Logani S: Immunohistochemical detection of p16INK4a in dysplastic lesions of the oral cavity. Mod Pathol. 2006, 19: 1310-6. 10.1038/modpathol.3800649.View ArticlePubMed
- Fregonesi PA, Teresa DB, Duarte RA, Neto CB, de Oliveira MR, Soares CP: p16(INK4A) immunohistochemical overexpression in premalignant and malignant oral lesions infected with human papillomavirus. J Histochem Cytochem. 2003, 51: 1291-7.View ArticlePubMed
- Powell EL, Leoni LM, Canto MI, Forastiere AA, Iocobuzio-Donahue CA, Wang JS, Maitra A, Montgomery E: Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications. Am J Surg Pathol. 2005, 29: 1497-504. 10.1097/01.pas.0000170349.47680.e8.View ArticlePubMed
- Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC: Mutations associated with familial melanoma impair p16INK4 function. Nat Genet. 1995, 10: 114-6. 10.1038/ng0595-114.View ArticlePubMed
- Miettinen M, Sobin LH, Lasota J: Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with longterm follow-up. Am J Surg Pathol. 2005, 29: 52-68. 10.1097/01.pas.0000146010.92933.de.View ArticlePubMed
- Franquemont DW: Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol. 1995, 103: 41-7.PubMed
- Vallmanya Llena FR, Laborda Rodríguez A, Lloreta Trull J, Cortadellas Angel R, Placer Santos J, Mas Gelabert A: Immunohistochemical expression of p53, p21, p16, and cyclin D1 in superficial bladder cancer. A tissue microarray study. Actas Urol Esp. 2006, 30: 754-62.View ArticlePubMed
- Huang HY, Huang WW, Lin CN, Eng HL, Li SH, Li CF, Lu D, Yu SC, Hsiung CY: Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol. 2006, 13: 1633-44. 10.1245/s10434-006-9188-4.View ArticlePubMed
- Kommoss S, du Bois A, Ridder R, Trunk MJ, Schmidt D, Pfisterer J, Kommoss F: Independent prognostic significance of cell cycle regulator proteins p16INK4a and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer. 2007, 96: 306-13. 10.1038/sj.bjc.6603531.PubMed CentralView ArticlePubMed
- Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Löning T: Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat. 2001, 67: 61-70. 10.1023/A:1010623308275.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.